Mereo BioPharma said a clinical trial for its treatment for bone disorder osteogenesis imperfecta failed to achieve its primary endpoint of increasing bone density in the wrist. The company, however, said the study achieved its 'secondary' endpoint of an increase in areal bone mineral density (BMD) at the lumbar spine at six and 12 months over baseline. For the secondary goal, the treatment reached statistical significance in the high and medium doses cohorts, with a clear dose-dependent response. Mean increases in areal BMD at the lumbar spine were 8.8%, 6.8% and 2.6% in the high, medium, and low dose cohorts at 12 months, respectively. However, mean changes in BMD of the wrist over baseline were 0.7%, minus 0.8% and 0.6% in the high, medium and low dose cohorts, respectively. 'These topline 12-month results from the Asteroid study demonstrate a clear, dose-dependent, statistically significant bone building effect of setrusumab at multiple anatomical sites in adult OI patients irrespective of OI subtype,' chief executive Denise Scots-Knight said. At 9:56am: (LON:MPH) Mereo Biopharma Group Ltd share price was -15.5p at 36p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.